Jug-PLGA-NPs, a New Form of Juglone with Enhanced Efficiency and Reduced Toxicity on Melanoma.
10.1007/s11655-021-3461-y
- Author:
Wu-Heng YUE
1
;
Lan-Qun QIN
2
;
Juan CAI
2
;
Rui MEI
1
;
Han-Qing QIAN
3
;
Zheng-Yun ZOU
4
Author Information
1. The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210008, China.
2. The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, 210008, China.
3. The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, 210008, China.
4. The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210008, China. zouzhengyun@njglyy.com.
- Publication Type:Journal Article
- Keywords:
Jug-PLGA-NPs;
PLGA;
juglone;
malignant melanoma;
nanoparticles
- MeSH:
Animals;
Cell Line, Tumor;
Delayed-Action Preparations/therapeutic use*;
Drug Carriers/therapeutic use*;
Melanoma/pathology*;
Mice;
Mice, Nude;
Nanoparticles;
Naphthoquinones;
Particle Size;
Polylactic Acid-Polyglycolic Acid Copolymer/therapeutic use*
- From:
Chinese journal of integrative medicine
2022;28(10):909-917
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To verrify the anti-tumor efficacy and toxicity between juglone (Jug) and Jug-loaded PLGA nanoparticles (Jug-PLGA-NPs).
METHODS:Jug-PLGA-NPs were prepared by ultrasonic emulsification. The anti-tumor activity of Jug (2, 3, 4 µg/mL) and Jug-PLGA-NPs (Jug: 2, 3, 4 µg/mL) in vitro was measured by MTT assay and cell apoptosis analysis. The distribution, anti-tumor effect and biological safety in vivo was evaluated on A375 nude mice.
RESULTS:With the advantage of good penetration and targeting properties, Jug-PLGA-NPs significantly inhibited proliferation and migration of melanoma cells both in vitro and in vivo (P<0.05 or P<0.01) with acceptable biocompatibility.
CONCLUSIONS:Jug can inhibit the growth of melanoma but is highly toxic. With the advantage of sustained release, tumor targeting, anti-tumor activity and acceptable biological safety, Jug-PLGA-NPs provide a new pharmaceutical form for future application of Jug.
